Juul MB, et al. - Researchers sought to explore treatment strategies and outcomes in diffuse large B-cell lymphoma (DLBCL) among patients aged 75 years or older. Using the Danish National Lymphoma Registry (LYFO), all Danish DLBCL-patients ≥ 75 years diagnosed from 2003 to 2012 were identified. This study was conducted on 1,011 patients. In a large proportion of elderly DLBCL-patients, the standard treatment was feasible with good outcomes. In patients above 80 years, no adverse impact on overall survival (OS) was seen after planned dose reduction. Among the oldest and most comorbid patients, less intensive regimens might be preferred.